Clinical Trial Update: A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 trial of alisertib (MLN8237) in adult East Asian participants with advanced solid tumors or lymphomas has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas
• Solid Tumors

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors, Lymphomas | Phase 1 | Status: COMPLETED | Results posted: 2019-03-15